The Mutational Landscape of Acute Myeloid Leukaemia Predicts Responses and Outcomes in Elderly Patients from the PETHEMA-FLUGAZA Phase 3 Clinical Trial

We sought to predict treatment responses and outcomes in older patients with newly diagnosed acute myeloid leukemia (AML) from our FLUGAZA phase III clinical trial (PETHEMA group) based on mutational status, comparing azacytidine (AZA) with fludarabine plus low-dose cytarabine (FLUGA). Mutational pr...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cancers 2021-05, Vol.13 (10), p.2458
Hauptverfasser:	Ayala, Rosa, Rapado, Inmaculada, Onecha, Esther, Martínez-Cuadrón, David, Carreño-Tarragona, Gonzalo, Bergua, Juan, Vives, Susana, Algarra, Jesus, Tormo, Mar, Martinez, Pilar, Serrano, Josefina, Herrera, Pilar, Ramos, Fernando, Salamero, Olga, Lavilla, Esperanza, Gil, Cristina, López Lorenzo, Jose, Vidriales, María, Labrador, Jorge, Falantes, José, Sayas, María, Paiva, Bruno, Barragán, Eva, Prosper, Felipe, Sanz, Miguel, Martínez-López, Joaquín, Montesinos, Pau
Format:	Artikel
Sprache:	eng
Schlagworte:	Acute myeloid leukemia Azacytidine Biomarkers Cancer therapies Chemotherapy Clinical trials Cytarabine Cytogenetics Dosage Fludarabine Gene frequency Genomics Medical prognosis Morphology Mutation Myeloid leukemia Next-generation sequencing Older people p53 Protein Patients Software Survival Variables
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!